Therapeutic window for combination therapy of A91 peptide and glutathione allows delayed treatment after spinal cord injury.
Immunisation with neural-derived peptides is a promising strategy in models of spinal cord (SC) injury. Recent studies have also demonstrated that the addition of glutathione monoethyl ester (GHSE) to this strategy further improves motor recovery, tissue protection and neuronal survival after SC injury. As it is realistic to envision that this combination therapy could be tested in clinical trials, the therapeutic window should be experimentally explored before implementing its use in SC-injured human beings. For this purpose, 50 rats (10 per group) were subjected to a moderate SC contusion. The combined therapy was initiated at 10 min., 24, 72 or 120 hr after injury. Motor recovery and the survival of rubrospinal (RS) and ventral horn (VH) neurones were evaluated 60 days after injury. Results showed a significant motor improvement even if the combined therapy was initiated up to 72 hr after injury. BBB scores were as follows: 10 min.: 10.5 ± 0.7, 24 hr: 10.7 ± 0.5, 72 hr: 11.0 ± 1.3 and PBS: 6.7 ± 1 (mean ± S.D.). Initiation of combined therapy 120 hr after injury had no beneficial effect on motor recovery. Survival of RS and VH neurones was significantly higher in animals treated during the first 72 hr than those treated only with PBS. In this case again, animals treated with combined therapy 120 hr after injury did not present significant survival of neurones. Treatment with this combined strategy has a clinically feasible therapeutic window. This therapy provides enough time to transport and diagnose the patient and allows the concomitant use of other neuroprotective therapies.
Facultad de Ciencias de la Salud, Universidad Anáhuac México Norte, Huixquilucan Edo. de México, México.
María
M
del Rayo Garrido
Raúl
R
Silva-García
Elisa
E
García
Susana
S
Martiñón
Mariana
M
Morales
Humberto
H
Mestre
Carmina
C
Flores-Domínguez
Adrian
A
Flores
Antonio
A
Ibarra
D000818:Animals; D000870:Anterior Horn Cells / Q000187:drug effects / Q000473:pathology; D002470:Cell Survival / Q000187:drug effects; D004195:Disease Models, Animal; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D005978:Glutathione / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000276:immunology; D009043:Motor Activity / Q000187:drug effects* / Q000502:physiology; D004676:Myelin Basic Protein / Q000276:immunology / Q000494:pharmacology*; D009474:Neurons / Q000187:drug effects / Q000473:pathology; D018696:Neuroprotective Agents / Q000008:administration & dosage* / Q000276:immunology; D051381:Rats; D017207:Rats, Sprague-Dawley; D013119:Spinal Cord Injuries / Q000276:immunology / Q000503:physiopathology / Q000628:therapy*; D013997:Time Factors; D061665:Time-to-Treatment
D004676:Myelin Basic Protein; D018696:Neuroprotective Agents; C042431:S-ethyl glutathione; D005978:Glutathione